GlassScriptPhysician profile
David Soma
NPI 1669867198
$3,697.42
in general payments reported to CMS, 2019-2025
31 companies · $1,502 in 2025
The $1,502 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.43 · 2020: $11.61 · 2021: $179 · 2022: $153 · 2023: $801 · 2024: $955 · 2025: $1,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,238 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,237.92 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $546.47 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $502.95 | 2021-2025 | Camzyos, Eliquis |
| Pfizer INC. | $460.27 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $282.86 | 2022-2025 | Onpattro |
| Novo Nordisk INC | $189.62 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.34 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $156.86 | 2023-2025 | |
| Heartflow, INC. | $142.17 | 2025 | |
| Abbott Laboratories | $140.74 | 2024-2025 | Navitor, Amplatzer Amulet |
| Amgen INC. | $119.20 | 2022-2025 | Repatha, Repatha |
| Philips North America LLC | $117.50 | 2025 | Diagnostic Ecg Service, Holter |
| Atricure, INC. | $107.87 | 2023-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $91.83 | 2023-2025 | Lifevest |
| Cardiva Medical, INC. | $78.07 | 2023-2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f, Cardiva Vascade Mvp Vvcs 6-12f |
| Astrazeneca Pharmaceuticals LP | $72.01 | 2024-2025 | Wainua, Lokelma, Andexxa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $64.14 | 2023-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $53.99 | 2023-2024 | Xarelto |
| Scpharmaceuticals INC. | $49.73 | 2025 | |
| Cleerly, INC. | $40.19 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Medtronic, INC. | $37.30 | 2021 | |
| Kestra Medical Technology Services, INC. | $37.29 | 2025 | Assure Wcd |
| Ancora Heart, INC. | $34.46 | 2024 | Accucinch |
| Actelion Pharmaceuticals US, INC. | $32.40 | 2024 | Uptravi, Opsumit |
| Impulse Dynamics (USA) INC. | $29.30 | 2023 | Optimizer |
| Regeneron Healthcare Solutions, INC. | $25.68 | 2024 | Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $24.37 | 2024 | Arcalyst |
| Lantheus Medical Imaging, INC. | $22.86 | 2023 | Definity |
| Angiodynamics, INC. | $22.41 | 2023 | Alphavac |
| Edwards Lifesciences Corporation | $18.29 | 2022 | |
| Lilly USA, LLC | $18.12 | 2025 | Zepbound |
| Esperion Therapeutics, INC. | $14.13 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Soma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.